P

Psyence Biomedical Ltd
NASDAQ:PBM

Watchlist Manager
Psyence Biomedical Ltd
NASDAQ:PBM
Watchlist
Price: 0.726 USD -9.14% Market Closed
Market Cap: 1.4m USD

Psyence Biomedical Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Psyence Biomedical Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
P
Psyence Biomedical Ltd
NASDAQ:PBM
Operating Income
-$1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Operating Income
$2.1B
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
-2%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Operating Income
-$340.8m
CAGR 3-Years
-45%
CAGR 5-Years
-63%
CAGR 10-Years
-48%
K
Knight Therapeutics Inc
TSX:GUD
Operating Income
-CA$11.5m
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
-1%
Spectral Medical Inc
TSX:EDT
Operating Income
-CA$6.7m
CAGR 3-Years
16%
CAGR 5-Years
5%
CAGR 10-Years
4%
Cipher Pharmaceuticals Inc
TSX:CPH
Operating Income
$12.8m
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
9%
No Stocks Found

Psyence Biomedical Ltd
Glance View

Market Cap
1.4m USD
Industry
N/A

Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

PBM Intrinsic Value
Not Available
P

See Also

What is Psyence Biomedical Ltd's Operating Income?
Operating Income
-1.3m USD

Based on the financial report for Dec 31, 2022, Psyence Biomedical Ltd's Operating Income amounts to -1.3m USD.

What is Psyence Biomedical Ltd's Operating Income growth rate?
Operating Income CAGR 1Y
-291%

Over the last year, the Operating Income growth was -291%.

Back to Top